Pharmacoepidemiology and Drug Safety
Journal Title
- Pharmacoepidemiology and Drug Safety
ISSN
- E 1099-1557 | P 1053-8569
Publisher
- John Wiley & Sons Inc.
Listed on(Coverage)
| JCR | 1999-2023 |
|---|---|
| SJR | 1999-2020;2022-2023 |
| CiteScore | 2011-2023 |
| SCI | 2010-2019 |
| SCIE | 2010-2024 |
| CC | 2016-2024 |
| SCOPUS | 2017-2024 |
| MEDLINE | 2016-2024 |
| EMBASE | 2016-2024 |
Active
- Active
based on the information
- SCOPUS:2024-10
Country
- USA
Aime & Scopes
- The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: /// design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; /// comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; /// methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; /// assessments of harm versus benefit in drug therapy; /// patterns of drug utilization; /// relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; /// evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.